Agendia MammaPrint Ultra-Low Risk

Patients with a MammaPrint Ultra-Low Risk signature have excellent outcomes regardless of age, clinical risk or treatment received   Prospective Validation of MammaPrint Ultra-Low Risk from the MINDACT trial1   MammaPrint® delivers significant guidance for endocrine management decisions for women with ER+, HER2-, lymph node negative breast cancer. Published in the Journal of Clinical Oncology in January…